The unfolded protein response mediates reversible tau phosphorylation induced by metabolic stress

Cell Death and Disease

Volumn 5, Issue 8, 2014, Pages

  Van Der Harg, J M ^a   Nolle A ^a   Zwart, R ^a   Boerema, A S ^b   Van Haastert, E S ^c   Strijkstra, A M ^b   Hoozemans, J J M ^c   Scheper, W ^a,d,e  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE REGULATED PROTEIN 78; MEMBRANE PROTEIN; PKR LIKE ENDOPLASMIC RETICULUM KINASE; PROTEIN IRE1 ALPHA; PROTEIN KINASE; TAU PROTEIN; TAUROURSODEOXYCHOLIC ACID; TUNICAMYCIN; UNCLASSIFIED DRUG; DEOXYGLUCOSE; EIF2AK3 PROTEIN, HUMAN; ERN1 PROTEIN, HUMAN; PROTEIN KINASE R; PROTEIN SERINE THREONINE KINASE; RIBONUCLEASE; TAUROCHENODEOXYCHOLIC ACID;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METABOLIC STRESS; NERVE CELL; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TORPOR; UNFOLDED PROTEIN RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CORTEX; COLD; CORPUS STRIATUM; DRUG EFFECTS; HAMSTER; HIPPOCAMPUS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGICAL STRESS; TUMOR CELL LINE;

ALZHEIMER DISEASE; ANIMALS; CELL LINE, TUMOR; CEREBRAL CORTEX; COLD TEMPERATURE; CORPUS STRIATUM; CRICETINAE; DEOXYGLUCOSE; EIF-2 KINASE; ENDORIBONUCLEASES; HIPPOCAMPUS; HUMANS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; TAU PROTEINS; TAUROCHENODEOXYCHOLIC ACID; TUNICAMYCIN; UNFOLDED PROTEIN RESPONSE;

EID: 84906852572     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.354     Document Type: Article

References (47)

1. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007; 8: 663-672.
2. Dixit R, Ross JL, Goldman YE, Holzbaur EL. Differential regulation of dynein and kinesin motor proteins by tau. Science 2008; 319: 1086-1089.
3. Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X et al. Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol Med 2005; 11: 164-169.
4. Morin P Jr., Storey KB. Mammalian hibernation: differential gene expression and novel application of epigenetic controls. Int J Dev Biol 2009; 53: 433-442.
5. Stieler JT, Bullmann T, Kohl F, Toien O, Bruckner MK, Hartig W et al. The physiological link between metabolic rate depression and tau phosphorylation in mammalian hibernation. PLoS One 2011; 6: e14530.
6. Dausmann KH, Glos J, Ganzhorn JU, Heldmaier G. Physiology: hibernation in a tropical primate. Nature 2004; 429: 825-826.
7. Yanagisawa M, Planel E, Ishiguro K, Fujita SC. Starvation induces tau hyperphosphorylation in mouse brain: implications for Alzheimer's disease. FEBS Lett 1999; 461: 329-333.
8. Kim B, Backus C, Oh S, Hayes JM, Feldman EL. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 2009; 150: 5294-5301.
9. Planel E, Tatebayashi Y, Miyasaka T, Liu L, Wang L, Herman M et al. Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci 2007; 27: 13635-13648.
10. Ke YD, Delerue F, Gladbach A, Gotz J, Ittner LM. Experimental diabetes mellitus exacerbates tau pathology in a transgenicmouse model of Alzheimer's disease. PLoS One 2009; 4: e7917.
11. Hoglinger GU, Lannuzel A, Khondiker ME, Michel PP, Duyckaerts C, Feger J et al. The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem 2005; 95: 930-939.
12. Frisardi V, Solfrizzi V, Seripa D, Capurso C, Santamato A, Sancarlo D et al. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res Rev 2010; 9: 399-417.
13. Hoozemans JJ, Veerhuis R, van Haastert ES, Rozemuller JM, Baas F, Eikelenboom P et al. The unfolded protein response is activated in Alzheimer's disease. Acta Neuropathol 2005; 110: 165-172.
14. Unterberger U, Hoftberger R, Gelpi E, Flicker H, Budka H, Voigtlander T. Endoplasmic reticulum stress features are prominent in Alzheimer disease but not in prion diseases in vivo. J Neuropathol Exp Neurol 2006; 65: 348-357.
15. Hoozemans JJ, van Haastert ES, Nijholt DA, Rozemuller AJ, Eikelenboom P, Scheper W. The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. Am J Pathol 2009; 174: 1241-1251.
16. Nijholt DA, van Haastert ES, Rozemuller AJ, Scheper W, Hoozemans JJ. The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies. J Pathol 2012; 226: 693-702.
17. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011; 334: 1081-1086.
18. Hoozemans JJ, Scheper W. Endoplasmic reticulum: the unfolded protein response is tangled in neurodegeneration. Int J Biochem Cell Biol 2012; 44: 1295-1298.
19. Hartig W, Stieler J, Boerema AS, Wolf J, Schmidt U, Weissfuss J et al. Hibernation model of tau phosphorylation in hamsters: selective vulnerability of cholinergic basal forebrain neurons - implications for Alzheimer's disease. Eur J Neurosci 2007; 25: 69-80.
20. Fu ZQ, Yang Y, Song J, Jiang Q, Lin ZC, Wang Q et al. LiCl attenuates thapsigargin-induced tau hyperphosphorylation by inhibiting GSK-3beta in vivo and in vitro. J Alzheimers Dis 2010; 21: 1107-1117.
21. Song L, De SP, Jope RS. Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem 2002; 277: 44701-44708.
22. Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S et al. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J Neurosci 2004; 24: 2401-2411.
23. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313: 1137-1140.
24. Xie Q, Khaoustov VI, Chung CC, Sohn J, Krishnan B, Lewis DE et al. Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology 2002; 36: 592-601.
25. Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, Grant SW et al. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl) -7H-p yrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem 2012; 55: 7193-7207.
26. Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci 2011; 14: 750-756.
27. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271-278.
28. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004; 53: 474-481.
29. Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2000; 97: 6037-6042.
30. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795-804.
31. Ishii H, Ishikawa H, Meguro K, Tashiro M, Yamaguchi S. Decreased cortical glucose metabolism in converters from CDR 0.5 to Alzheimer's disease in a community: the Osaki-Tajiri Project. Int Psychogeriatr 2009; 21: 148-156.
32. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003; 30: 1104-1113.
33. Mosconi L, Andrews RD, Matthews DC. Comparing brain amyloid deposition, glucose metabolism, and atrophy in mild cognitive impairment with and without a family history of dementia. J Alzheimers Dis 2013; 35: 509-524.
34. Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 2003; 54: 343-351.
35. Burns CM, Chen K, Kaszniak AW, Lee W, Alexander GE, Bandy D et al. Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. Neurology 2013; 80: 1557-1564.
36. Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron 2013; 78: 256-268.
37. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122: 1316-1338.
38. Abisambra JF, Jinwal UK, Blair LJ, O'Leary JC III, Li Q, Brady S et al. Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation. J Neurosci 2013; 33: 9498-9507.
39. Stoveken BJ. Tau pathology as a cause and consequence of the UPR. J Neurosci 2013; 33: 14285-14287.
40. Roussel BD, Kruppa AJ, Miranda E, Crowther DC, Lomas DA, Marciniak SJ. Endoplasmic reticulum dysfunction in neurological disease. Lancet Neurol 2013; 12: 105-118.
41. Scheper W, Hoozemans JJ. A new PERKspective on neurodegeneration. Sci Transl Med 2013; 5: 206fs37.
42. Ma T, Trinh MA, Wexler AJ, Bourbon C, Gatti E, Pierre P et al. Suppression of eIF2alpha kinases alleviates Alzheimer's disease-related plasticity and memory deficits. Nat Neurosci 2013; 16: 1299-1305.
43. Moreno JA, Halliday M, Molloy C, Radford H, Verity N, Axten JM et al. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci Transl Med 2013; 5: 206ra138.
44. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Martin MG et al. Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration. Nature 2012; 485: 507-511.
45. Hoglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 2011; 43: 699-705.
46. Nijholt DA, Nolle A, van Haastert ES, Edelijn H, Toonen RF, Hoozemans JJ et al. Unfolded protein response activates glycogen synthase kinase-3 via selective lysosomal degradation. Neurobiol Aging 2013; 34: 1759-1771.
47. Hopman AH, Ramaekers FC, Speel EJ. Rapid synthesis of biotin-, digoxigenin-, trinitrophenyl-, and fluorochrome-labeled tyramides and their application for In situ hybridization using CARD amplification. J Histochem Cytochem 1998; 46: 771-777.